Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, February 6, 2015

Scientists Discover a Key Pathway That Protects Cells Against Death by Stress

What is your doctor doing to protect you against the stress of no stroke protocols for getting to 100% recovery? You're under a lot of stress about recovery so DEMAND this protection against cell death.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=149416&CultureCode=en
When it comes to protecting cells from death brought on by the calamities of environmental stress, the human body is particularly ingenious. From cellular components that suck up misfolded proteins to a vigilant immune system, the ways we protect our cells (and ourselves) are many and mysterious.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have now uncovered the workings of another cell-protection device, one that may play a major role in a number of age-related diseases, including diabetes and Parkinson’s, Alzheimer’s and Huntington’s diseases.
The study, led by Srinivasa Subramaniam, a TSRI assistant professor, and Solomon H. Snyder, a neuroscience professor at Johns Hopkins University School of Medicine, was published February 5 in the journal Cell Reports.
More or Less Acceleration
The study focuses on a new pathway through which Rheb, a regulator that many believe is active in the brain’s ability to change in response to learning, actually plays two roles, rather than one—stimulating and inhibiting protein synthesis.
The interplay between the two roles may be the key that enables cells to alter protein synthesis and protect the cell in response to varying environmental stresses.
“We found Rheb acts like the gas pedal in a car,” Subramaniam said. “It can either increase translation or decrease it. And because translation is a fundamental process that is affected in a lot of diseases, we now think that Rheb may act like a switch in some disease states—helping to turn them off and on.”
Rheb is known to bind and activate mTOR, a developmentally important gene that integrates signals from multiple pathways and regulates critical cell functions such as protein synthesis. Besides its role as an activator of mTOR, which plays a major role in conditions from diabetes to neurodegenerative disease, the mTOR-independent role of Rheb is less known. The new study defines crucial mTOR-independent effects of Rheb. Results showed that, when stressed, Rheb instead inhibits protein synthesis by amplifying the phosphorylation (adding a phosphate group to a protein to alter its function) of another protein known eIF2a. As a result, cell resources can be conserved rather than squandered when the environment is challenging.
“We don’t really understand the full role of the Rheb-mTOR pathway, but we have uncovered a new fundamental process of Rheb that is independent of mTOR and very intriguing,” said Neelam Shahani, a member of Subramaniam’s lab who was co-first author of the study with Richa Tyagi of Johns Hopkins University School of Medicine. “Rheb can inhibit protein synthesis, and we know that protein misfolding via environmental stress factors is present in a lot of diseases.”
Subramaniam noted that, intriguingly, an earlier study had suggested the Rheb pathway had been implicated in Alzheimer’s disease. “We also want to look at Rheb’s role in other neurodegenerative diseases,” he said.
In addition to Subramaniam, Snyder, Shahani and Tyagi, authors of the study, “Rheb Inhibits Protein Synthesis by Activating the PERK-eIF2α Signaling Cascade,” include Max Ferretti, William Pryor, Supriya Swarnkar and Katrin Karbstein of TSRI; Lindsay Gorgen of Florida Atlantic University; as well as Paul F. Worley and Po Yu Chen of Johns Hopkins University School of Medicine.
This work was supported by the State of Florida, the O'Keeffe Neuroscience Scholar Award and the United States Public Health Service (DA000266).

No comments:

Post a Comment